JP2020535803A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535803A5
JP2020535803A5 JP2020516666A JP2020516666A JP2020535803A5 JP 2020535803 A5 JP2020535803 A5 JP 2020535803A5 JP 2020516666 A JP2020516666 A JP 2020516666A JP 2020516666 A JP2020516666 A JP 2020516666A JP 2020535803 A5 JP2020535803 A5 JP 2020535803A5
Authority
JP
Japan
Prior art keywords
virus
vector
nucleic acid
promoter
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535803A (ja
JP7248658B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052221 external-priority patent/WO2019060726A1/en
Publication of JP2020535803A publication Critical patent/JP2020535803A/ja
Publication of JP2020535803A5 publication Critical patent/JP2020535803A5/ja
Application granted granted Critical
Publication of JP7248658B2 publication Critical patent/JP7248658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516666A 2017-09-22 2018-09-21 バリアントRNAi Active JP7248658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561843P 2017-09-22 2017-09-22
US62/561,843 2017-09-22
PCT/US2018/052221 WO2019060726A1 (en) 2017-09-22 2018-09-21 Variant rnai

Publications (3)

Publication Number Publication Date
JP2020535803A JP2020535803A (ja) 2020-12-10
JP2020535803A5 true JP2020535803A5 (enExample) 2021-10-28
JP7248658B2 JP7248658B2 (ja) 2023-03-29

Family

ID=64017428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516666A Active JP7248658B2 (ja) 2017-09-22 2018-09-21 バリアントRNAi

Country Status (19)

Country Link
US (3) US11603529B2 (enExample)
EP (1) EP3684932A1 (enExample)
JP (1) JP7248658B2 (enExample)
KR (1) KR102686857B1 (enExample)
CN (1) CN111356763B (enExample)
AR (1) AR113134A1 (enExample)
AU (2) AU2018335410B2 (enExample)
BR (1) BR112020005569A2 (enExample)
CA (1) CA3076191A1 (enExample)
CO (1) CO2020003187A2 (enExample)
IL (1) IL273394B2 (enExample)
MX (2) MX2020003095A (enExample)
MY (1) MY205041A (enExample)
PH (1) PH12020550117A1 (enExample)
SG (1) SG11202002488UA (enExample)
TW (1) TWI902656B (enExample)
UY (1) UY37897A (enExample)
WO (1) WO2019060726A1 (enExample)
ZA (1) ZA202001586B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3255657A1 (en) 2015-02-10 2025-12-01 Genzyme Corporation VARIANT RNAi
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
MX2020003095A (es) 2017-09-22 2020-10-15 Genzyme Corp Arni variante.
CN112980837B (zh) * 2019-12-13 2023-07-04 深圳艾码生物科技有限公司 一种抑制HTT基因表达的siRNA及其前体和应用
EP4133090A1 (en) * 2020-04-07 2023-02-15 Lung Biotechnology PBC Adenoviral expression vector and methods and cell lines for production
EP4317434A4 (en) * 2021-03-30 2025-04-16 Nanjing University RNA DELIVERY SYSTEM FOR THE TREATMENT OF HUNTINGTON'S DISEASE
JP2025538441A (ja) * 2022-11-16 2025-11-28 フォージ バイオロジクス,インコーポレイテッド アデノウイルスヘルパープラスミド
WO2025160434A1 (en) * 2024-01-26 2025-07-31 Genzyme Corporation Artificial micrornas targeting huntington's disease
WO2025250616A1 (en) * 2024-05-29 2025-12-04 The Regents Of The University Of California Methods and materials for treating huntington's disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
JP2004101787A (ja) 2002-09-09 2004-04-02 Fuji Xerox Co Ltd 画像形成装置及び現像装置
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2004239114B2 (en) 2003-05-14 2008-03-13 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
CA2596588C (en) * 2005-01-31 2017-06-27 University Of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8173614B2 (en) * 2007-01-03 2012-05-08 Medtronic, Inc. Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
WO2008134646A2 (en) 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
DK2164967T3 (en) 2007-05-31 2015-10-19 Univ Iowa Res Found Reduction of off-target rna interferenstoksicitet
CA2711585A1 (en) 2008-02-04 2009-08-13 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US8318924B2 (en) 2008-02-14 2012-11-27 Michael Paul Marie Gantier Immunostimulatory siRNA molecules
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
DK2561073T3 (en) * 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
CA2865011C (en) * 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CN103224556B (zh) * 2013-01-31 2015-04-15 清华大学 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用
US9550989B2 (en) 2013-10-03 2017-01-24 Washington University Rational design of microRNA-siRNA chimeras for multi-functional target suppression
MX391904B (es) 2013-11-11 2025-03-12 Sangamo Biosciences Inc Un represor genetico para usarse en el tratamiento de la enfermedad de huntington.
PT3628334T (pt) * 2014-03-21 2023-09-26 Genzyme Corp Terapia genética para retinopatia pigmentar
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
AU2015264263B2 (en) 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
AU2015370903B2 (en) * 2014-12-24 2021-06-17 Uniqure Ip B.V. RNAi induced huntingtin gene suppression
CA3255657A1 (en) 2015-02-10 2025-12-01 Genzyme Corporation VARIANT RNAi
IL297576B2 (en) * 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
MX2020003095A (es) 2017-09-22 2020-10-15 Genzyme Corp Arni variante.
TW202509215A (zh) 2018-08-03 2025-03-01 美商健臻公司 針對α-突觸核蛋白的變體RNAi

Similar Documents

Publication Publication Date Title
JP2021534814A5 (enExample)
JP2018506304A5 (enExample)
IL273394B1 (en) Variant rnai
JP2020019772A5 (enExample)
JP2020114235A5 (enExample)
JP2021106619A5 (enExample)
JP2022549380A5 (enExample)
JP2017535266A5 (enExample)
JP2022524434A5 (enExample)
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
RU2018140499A (ru) Способы и композиции для лечения хореи гентингтона
JP2019533439A5 (enExample)
JP2024099770A5 (enExample)
JP2017509632A5 (enExample)
JP2020519284A5 (enExample)
JP2023515692A5 (enExample)
JP2022525302A5 (enExample)
JP2022551744A5 (enExample)
JP2021522836A5 (enExample)
JP2024508696A5 (enExample)
JP2023541443A5 (enExample)
IL292264B1 (en) Aav transfer cassette
JP2023524024A5 (enExample)
JP2023537358A5 (enExample)
JP2020519294A5 (enExample)